Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Novo Nordisk (NVO) has multiple positive catalysts on the horzon, including its recent decision to offer subscriptions to Wegovy, its popular GLP-1 weight-loss drug. Still, given a forthcoming — and potentially huge — negative catalyst facing the company, investors may want to refrain from buying NVO stock for now.

What's going on with Novo Nordisk? Let's take a closer look.

Fundamentals

See More
  • Market Capitalization, $K 883,953,792
  • Shares Outstanding, K 944,819
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.51
  • Price/Sales 13.84
  • Price/Cash Flow 37.97
  • Price/Book 34.01

Options Overview Details

View History
  • Implied Volatility 42.53% (-0.09%)
  • Historical Volatility 34.98%
  • IV Percentile 83%
  • IV Rank 41.58%
  • IV High 64.53% on 04/07/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 7) 31.15 (3.33%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 60,095
  • Volume Avg (30-Day) 35,701
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 330,208
  • Open Int (30-Day) 322,349
  • Expected Range 904.43 to 966.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $7.54
  • Number of Estimates 8
  • High Estimate $8.56
  • Low Estimate $6.61
  • Prior Year $3.34
  • Growth Rate Est. (year over year) +125.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
877.11 +6.67%
on 03/27/26
1,020.01 -8.28%
on 03/03/26
-82.39 (-8.09%)
since 03/02/26
3-Month
877.11 +6.67%
on 03/27/26
1,133.95 -17.49%
on 01/08/26
-144.78 (-13.40%)
since 01/02/26
52-Week
623.78 +49.99%
on 08/08/25
1,133.95 -17.49%
on 01/08/26
+117.36 (+14.34%)
since 04/02/25

Most Recent Stories

More News
Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

NVO : 36.98 (+1.37%)
HIMS : 19.14 (-3.53%)
LLY : 935.58 (-1.98%)
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

CNTA : 39.69 (-0.43%)
LLY : 935.58 (-1.98%)
Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...

ALK : 37.33 (-0.85%)
MPC : 241.73 (+1.50%)
SNDK : 701.59 (+1.28%)
HL : 19.18 (unch)
CDE : 19.09 (-0.10%)
LITE : 826.88 (+8.14%)
OXY : 62.97 (+1.19%)
NCNO : 17.10 (+3.20%)
GLW : 147.92 (+3.89%)
FANG : 193.88 (+1.71%)
STX : 429.36 (+1.47%)
WDC : 294.97 (-0.93%)
Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

LLY : 935.58 (-1.98%)
Eli Lilly (LLY) Stock Trades Up, Here Is Why

Eli Lilly (LLY) Stock Trades Up, Here Is Why

LLY : 935.58 (-1.98%)
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial 1

LLY : 935.58 (-1.98%)
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.69 (-0.43%)
LLY : 935.58 (-1.98%)
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

XLV : 146.81 (-0.62%)
LLY : 935.58 (-1.98%)
Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MRK : 120.87 (+0.02%)
LLY : 935.58 (-1.98%)
ABBV : 208.84 (-2.86%)
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders

CNTA : 39.69 (-0.43%)
LLY : 935.58 (-1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 979.84
2nd Resistance Point 968.76
1st Resistance Point 952.17
Last Price 935.58
1st Support Level 924.50
2nd Support Level 913.43
3rd Support Level 896.84

See More

52-Week High 1,133.95
Fibonacci 61.8% 939.07
Last Price 935.58
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.